Serum Institute to stockpile Novavax vaccine candidate from around April

SII will start stockpiling millions of doses of the Novavax coronavirus vaccine candidate starting around April

Topics
Serum Institute of India | Coronavirus Vaccine

Reuters  |  NEW DELHI 

Coronavirus, vaccine, covid, drugs, clinical trials
Representational image

NEW DELHI (Reuters) - The Serum Institute of India, the world's biggest vaccine maker, will start stockpiling millions of doses of the Novavax vaccine candidate starting around April, CEO Adar Poonawalla told the Reuters Next conference on Thursday.

"Upwards of 40-50 million doses per month is what we are trying to stockpile starting from April," he said.

 

For more coverage from the Reuters Next conference please click here or http://www.reuters.com/business/reuters-next

 

(Reporting by Euan Rocha; editing by Jason Neely)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Serum Institute of India
First Published: Thu, January 14 2021. 15:47 IST
RECOMMENDED FOR YOU